151 related articles for article (PubMed ID: 35814563)
21. MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells.
Yee D; Shah KM; Coles MC; Sharp TV; Lagos D
J Biol Chem; 2017 Dec; 292(50):20683-20693. PubMed ID: 29066622
[TBL] [Abstract][Full Text] [Related]
22. Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS.
Yoyen-Ermis D; Tunali G; Tavukcuoglu E; Horzum U; Ozkazanc D; Sutlu T; Buyukasik Y; Esendagli G
Sci Rep; 2019 Aug; 9(1):11697. PubMed ID: 31406210
[TBL] [Abstract][Full Text] [Related]
23. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.
Van Der Kraak L; Goel G; Ramanan K; Kaltenmeier C; Zhang L; Normolle DP; Freeman GJ; Tang D; Nason KS; Davison JM; Luketich JD; Dhupar R; Lotze MT
J Immunother Cancer; 2016; 4():65. PubMed ID: 27777774
[TBL] [Abstract][Full Text] [Related]
24. Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma.
Liang X; Gao H; Xiao J; Han S; He J; Yuan R; Yang S; Yao C
Front Immunol; 2023; 14():1185985. PubMed ID: 37334368
[TBL] [Abstract][Full Text] [Related]
25. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.
Thiem A; Hesbacher S; Kneitz H; di Primio T; Heppt MV; Hermanns HM; Goebeler M; Meierjohann S; Houben R; Schrama D
J Exp Clin Cancer Res; 2019 Sep; 38(1):397. PubMed ID: 31506076
[TBL] [Abstract][Full Text] [Related]
26. Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
Hänze J; Wegner M; Noessner E; Hofmann R; Hegele A
Target Oncol; 2020 Jun; 15(3):377-390. PubMed ID: 32495158
[TBL] [Abstract][Full Text] [Related]
27. MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas.
Wang QW; Sun LH; Zhang Y; Wang Z; Zhao Z; Wang ZL; Wang KY; Li GZ; Xu JB; Ren CY; Ma WP; Wang HJ; Li SW; Zhu YJ; Jiang T; Bao ZS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34667077
[TBL] [Abstract][Full Text] [Related]
28. MiR-10b-5p Impairs TET2-Mediated Inhibition of PD-L1 Transcription Thus Promoting Immune Evasion and Tumor Progression in Glioblastoma.
Du W; Chen D; Wei K; Yu D; Gan Z; Xu G; Yao G
Tohoku J Exp Med; 2023 Jul; 260(3):205-214. PubMed ID: 37019647
[TBL] [Abstract][Full Text] [Related]
29. Triptolide reverses helper T cell inhibition and down-regulates IFN-γ induced PD-L1 expression in glioma cell lines.
Zhang L; Yu JS
J Neurooncol; 2019 Jul; 143(3):429-436. PubMed ID: 31152305
[TBL] [Abstract][Full Text] [Related]
30. Glioma-associated mesenchymal stem cells-mediated PD-L1 expression is attenuated by Ad5-Ki67/IL-15 in GBM treatment.
Zhang Q; Zhang J; Wang P; Zhu G; Jin G; Liu F
Stem Cell Res Ther; 2022 Jun; 13(1):284. PubMed ID: 35765095
[TBL] [Abstract][Full Text] [Related]
31. Retracted: IFN-
Intelligence And Neuroscience C
Comput Intell Neurosci; 2023; 2023():9845607. PubMed ID: 38074393
[TBL] [Abstract][Full Text] [Related]
32. Triptolide reduces PD-L1 through the EGFR and IFN-γ/IRF1 dual signaling pathways.
Xie Y; Ding J; Gao J; Zhang J; Cen S; Zhou J
Int Immunopharmacol; 2023 May; 118():109993. PubMed ID: 36931170
[TBL] [Abstract][Full Text] [Related]
33. Involvement of ERK and JNK pathways in IFN-γ-induced B7-DC expression on tumor cells.
Deng J; Qian Y; Geng L; Xie H; Wang Y; Jiang G; Zhou L; Zhang M; Zheng S
J Cancer Res Clin Oncol; 2011 Feb; 137(2):243-50. PubMed ID: 20390427
[TBL] [Abstract][Full Text] [Related]
34. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
Su L; Guo W; Lou L; Nie S; Zhang Q; Liu Y; Chang Y; Zhang X; Li Y; Shen H
Mol Carcinog; 2020 May; 59(5):520-532. PubMed ID: 32134157
[TBL] [Abstract][Full Text] [Related]
35. MYC inhibition increases PD-L1 expression induced by IFN-γ in hepatocellular carcinoma cells.
Zou J; Zhuang M; Yu X; Li N; Mao R; Wang Z; Wang J; Wang X; Zhou H; Zhang L; Shi Y
Mol Immunol; 2018 Sep; 101():203-209. PubMed ID: 30007230
[TBL] [Abstract][Full Text] [Related]
36. Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours.
Martin V; Chiriaco C; Modica C; Acquadro A; Cortese M; Galimi F; Perera T; Gammaitoni L; Aglietta M; Comoglio PM; Vigna E; Sangiolo D
Br J Cancer; 2019 Mar; 120(5):527-536. PubMed ID: 30723303
[TBL] [Abstract][Full Text] [Related]
37. PD-L1/PD-1 Axis in Glioblastoma Multiforme.
Litak J; Mazurek M; Grochowski C; Kamieniak P; Roliński J
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661771
[TBL] [Abstract][Full Text] [Related]
38. Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells.
Coombs MRP; Harrison ME; Hoskin DW
Cancer Lett; 2016 Oct; 380(2):424-433. PubMed ID: 27378243
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
40. PTRF/Cavin-1 as a Novel RNA-Binding Protein Expedites the NF-κB/PD-L1 Axis by Stabilizing lncRNA NEAT1, Contributing to Tumorigenesis and Immune Evasion in Glioblastoma.
Yi K; Cui X; Liu X; Wang Y; Zhao J; Yang S; Xu C; Yang E; Xiao M; Hong B; Fang C; Kang C; Tan Y; Wang Q
Front Immunol; 2021; 12():802795. PubMed ID: 35069587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
